Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.

NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.

NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.

The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.

for additional information contact jameshamilton@nanovalent.com